CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 82 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-07 | Rubin Eyal Sr. VP and CFO | Grant or award · Stock Options (Right to Buy) | +350,000 | 350,000 | ||
| 2022-09-07 | Bashan Dror President and CEO | Grant or award · Stock Options (Right to Buy) | +750,000 | 750,000 | ||
| 2022-09-07 | Schwartz Aharon Director | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2022-09-07 | Bronfeld Zeev Director | Grant or award · Stock Options (Right to Buy) | +100,000 | 100,000 | ||
| 2022-09-07 | Bar-Shalev Amos Director | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2022-09-07 | Melincoff Gwen A Director | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2022-09-07 | Boudes Pol F Director | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2022-06-30 | Ben Zvi Shmuel Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2022-04-11 | Bashan Dror President and CEO | Purchase | +68,000 | $1.50 | $102K | 68,000 |
| 2022-02-25 | Rubin Eyal Sr. VP and CFO | Grant or award | +121,951 | 368,097 | ||
| 2022-02-25 | Bashan Dror President and CEO | Grant or award | +637,531 | 1,085,458 | ||
| 2021-06-03 | Dexcel Pharma Technologies Ltd. 10% owner | Sale | −857,506 | $2.25 | $1.9M | 3,637,314 |
| 2021-06-02 | Dexcel Pharma Technologies Ltd. 10% owner | Sale | −61,211 | $2.56 | $157K | 4,494,820 |
| 2020-08-11 | Rubin Eyal Sr. VP and CFO | Grant or award | +246,146 | 246,146 | ||
| 2020-08-11 | Bashan Dror President and CEO | Grant or award | +447,927 | 447,927 | ||
| 2020-08-11 | Rubin Eyal Sr. VP and CFO | Grant or award | +246,146 | 246,146 | ||
| 2020-08-11 | Bashan Dror President and CEO | Grant or award | +447,927 | 447,927 | ||
| 2020-08-11 | Naos Yaron Sr. VP, Operations | Grant or award · Stock Options (Right to Buy) | +122,656 | 122,656 | ||
| 2020-07-05 | Hayon Yael VP, Research & Development | Grant or award · Stock Options (Right to Buy) | +129,771 | 129,771 | ||
| 2020-06-07 | Almon Einat Brill SVP, Chief Development Officer | Grant or award · Stock Options (Right to Buy) | +196,995 | 196,995 |
Page 4 of 7 · 139 trades